Latest News & Updates
Mismatch repair deficiency may serve as an immuno-oncology biomarker and may illustrate the clinical utility of analyzing the number of mutations per tumor.
The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.
Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.
New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.
Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.
Latest Peer Exchange Discussions
Thomas E. Hutson, DO, PharmD, and David F. McDermott, MD, assess adjuvant therapy strategies in individuals with renal cell carcinoma at high risk of recurrence. View Now
Led by moderator Mark A. Socinski, MD, panelists Mary Jo Fidler, MD; Roy S. Herbst, MD, PhD; and Geoffrey R. Oxnard, MD, discuss ASCO 2015 data on ADZ9291 and rociletinib, which continue to show impressive efficacy and safety profiles. View Now
Michael Kolodziej, MD, and Jeffrey C. Ward, MD, explain why payment reform in oncology is far more complicated than it may seem. View Now
Most Popular Right Now
Online CME Activities